Systemic Cell Therapy using human mononuclear cord blood cells (hUCBCs) in patients with Acute Severe Contusion Spinal Cord Injury (ASIA A, B): Phases I/IIa of randomized open-label safety and primary efficiency clinical study
motor deficit up to 53% compared to placebo and decrease in myelopathy area volume according to 7,0 Tl MRI examination. Materials and Methods: Phases I/IIa randomized open-label ... conducted efficiency analysis…

